Nizatidine
Overview
Nizatidine is oral H-2-receptor antagonist similar to cimetidine, famotidine, and ranitidine. It currently is indicated for gastroesophageal reflux disease (GERD), short-term and maintenance treatment of duodenal ulcer, and short-term treatment of active benign gastric ulcer. It was originally approved by the FDA in April 1988. It competitively inhibits the binding of histamine to the H-2-receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. It may aid in gastromucosal healing, and it may protect the mucosa from the irritant effects caused by aspirin and nonsteroidal antiinflammatory agents..
Categories
- 17 Gastrointestinal drugs
- 17.1 Antacids/ Antiflatulents/ Antipeptic ulcerants
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Nizatidine's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 150 mg | 150 (150) | 12 hourly | PO | Maintenance dosr at night intially. |
| 150 mg | 150 (150) | 24 hourly | PO | |
Paedriatic Dosage (20kg)
|
| | | | Not recommended for this age group |
Neonatal Dosage (3kg)
|
| | | | Not recommended in this age group |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Back to top
Previous Drug Generic - Next Drug Generic